Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,239,759
  • Shares Outstanding, K 37,230
  • Annual Sales, $ 272,300 K
  • Annual Income, $ -5,140 K
  • EBIT $ 31 M
  • EBITDA $ 54 M
  • 60-Month Beta 0.05
  • Price/Sales 4.63
  • Price/Cash Flow 40.94
  • Price/Book 25.16

Options Overview Details

View History
  • Implied Volatility 79.86% (+0.20%)
  • Historical Volatility 103.98%
  • IV Percentile 60%
  • IV Rank 45.01%
  • IV High 116.95% on 04/08/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 17) 3.61 (10.85%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 1,176
  • Volume Avg (30-Day) 1,570
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 40,221
  • Open Int (30-Day) 41,191
  • Expected Range 29.69 to 36.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.67
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +23.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.03 +0.83%
on 03/23/26
54.29 -38.66%
on 03/02/26
-20.88 (-38.54%)
since 02/27/26
3-Month
33.03 +0.83%
on 03/23/26
54.85 -39.29%
on 01/07/26
-16.79 (-33.52%)
since 12/26/25
52-Week
20.85 +59.71%
on 04/09/25
54.85 -39.29%
on 01/07/26
+7.09 (+27.05%)
since 03/28/25

Most Recent Stories

More News
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private...

HROW : 33.30 (-1.57%)
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer,...

HROW : 33.30 (-1.57%)
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts...

HROW : 33.30 (-1.57%)
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference

NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...

HROW : 33.30 (-1.57%)
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug...

HROW : 33.30 (-1.57%)
Harrow: Q4 Earnings Snapshot

Harrow: Q4 Earnings Snapshot

HROW : 33.30 (-1.57%)
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3...

HROW : 33.30 (-1.57%)
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 33.30 (-1.57%)
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber...

HROW : 33.30 (-1.57%)
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based...

HROW : 33.30 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 35.50
2nd Resistance Point 34.97
1st Resistance Point 34.13
Last Price 33.30
1st Support Level 32.76
2nd Support Level 32.23
3rd Support Level 31.39

See More

52-Week High 54.85
Fibonacci 61.8% 41.86
Fibonacci 50% 37.85
Fibonacci 38.2% 33.84
Last Price 33.30
52-Week Low 20.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.